Interstitial pneumonitis following sequential administration of programmed death-1/programmed death-ligand1 inhibitors and epidermal growth factor receptor-tyrosine kinase inhibitors for non-small cell lung cancer: A matched‐pair cohort study using a nationwide inpatient database